
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled in Sanofi-Aventis U.S. v. HHS et al. Cases raising similar legal questions are pending in the District of Columbia and 7th Circuits.